Related Experiment Video
Updated: May 8, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Melanoma brain metastases: an unmet challenge in the era of active therapy
Vikram Gorantla1, John M Kirkwood, Hussein A Tawbi
1Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract:
Metastatic disease to the brain is a frequent manifestation of melanoma and is associated with significant morbidity and mortality and poor prognosis. Surgery and stereotactic radiosurgery provide local control but less frequently affect the overall outcome of melanoma brain metastases (MBM). The role of systemic therapies for active brain lesions has been largely underinvestigated, and patients with active brain lesions are excluded from the vast majority of clinical trials. The advent of active systemic therapy has revolutionized the care of melanoma patients, but this benefit has not been systematically translated into intracranial activity. In this article, we review the biology and clinical outcomes of patients with MBM, and the evidence supporting the use of radiation, surgery, and systemic therapy in MBM. Prospective studies that included patients with active MBM have shown clinical intracranial activity that parallels systemic activity and support the inclusion of patients with active MBM in clinical trials involving novel agents and combination therapies.
Insights
Melanoma brain metastases (MBM) often have poor outcomes. Systemic therapies show promise for intracranial activity, suggesting MBM patients should be included in clinical trials.
Area of Science:
- Oncology
- Neurology
- Dermatology
Background:
- Melanoma brain metastases (MBM) are common, leading to poor prognosis.
- Current treatments like surgery and radiosurgery offer limited impact on overall survival.
- Systemic therapies have improved melanoma care but their intracranial efficacy remains understudied.
Purpose of the Study:
- To review the biology and clinical outcomes of MBM.
- To evaluate the evidence for radiation, surgery, and systemic therapy in MBM.
- To highlight the need for including MBM patients in clinical trials.
Main Methods:
- Literature review of MBM biology, treatment outcomes, and clinical trial data.
- Analysis of systemic therapy efficacy in patients with active brain lesions.
- Examination of prospective studies on MBM treatment.
Main Results:
- Intracranial activity of systemic therapies in MBM parallels systemic response.
- Prospective studies demonstrate clinical benefit of systemic agents in active MBM.
- Exclusion of MBM patients from trials limits understanding of treatment efficacy.
Conclusions:
- Systemic therapies demonstrate significant intracranial activity in melanoma brain metastases.
- Inclusion of patients with active MBM in clinical trials is crucial for advancing treatment.
- Further research is needed to optimize systemic therapy for MBM.
Related Concept Videos
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy